Trial Profile
An Open Label Trial Evaluating Cardiac T2 in Beta-thalassemia Patients on Deferasirox (ICL670) Treatment for 18 Months
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Beta-thalassaemia
- Focus Therapeutic Use
- Sponsors Novartis
- 10 Sep 2014 New trial record